eftilagimod alpha,pembrolizumab
immutep,merck
['improve', 'tacti002', 'pdl']
tacti002 solublelag3+pembro
phase 2. n-114. no crs. orr 38.6% itt, irecist 42%. orrs improved by increasing pdl1%. impressive spiders esp in responders, translates to encouraging pfs any pdl1. &lt;10% tr-discont rate interesting combo to keep and eye on #asco22 
Thoracic Oncologist @royalmarsdenNHS, Professor @ICR_London; Chair @BTOGorg; views are my own. Wear a mask, keep distant, get the vaccine & then a booster!